

TEPEZZA Coding at a Glance

This guide provides a streamlined view of codes that are commonly associated with Thyroid Eye Disease (TED) or TEPEZZA® (teprotumumab-trbw). **The following codes are not inclusive and should be used for guidance only. Coverage and reimbursement will vary from payor to payor.**

ICD-10-CM Diagnosis Code ^{1,*}		Description
E05.00		Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm
NDC ²		Description
10-digit NDC	75987-130-15	500 mg teprotumumab-trbw in a single-dose vial (lyophilized powder for injection for intravenous infusion)
11-digit NDC	75987-0130-15	

***TEPEZZA has a permanent, product-specific HCPCS J-code.³ Additional ICD-10-CM diagnosis codes may be used to fully describe the patient's condition and associated manifestations. Please visit TEPEZZAhcp.com for a supplementary listing of codes.**

HCPCS Drug Code ^{3,4}		
J3241		Injection, teprotumumab-trbw, 10 mg
HCPCS Drug Administration Codes ⁴		
Specialty Pharmacy Providers	S9329	Home infusion therapy, chemotherapy infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with S9330 or S9331)
	S9379	Home infusion therapy, infusion therapy, not otherwise classified; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
	S9810	Home therapy; professional pharmacy services for provision of infusion, specialty drug administration, and/or disease state management, not otherwise classified, per hour (do not use this code with any per diem code)

Modifier ⁵	Description	Appropriate Use
JW	Drug amount discarded/not administered to any patient	Append to J3241 when there was a discarded drug amount
JZ	Zero drug amount discarded/not administered to any patient	Append to J3241 when there was NO discarded drug amount

HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; NDC, National Drug Code.



Amgen By Your Side is a support program for patients prescribed TEPEZZA. Our dedicated team is your patient's partner, committed to providing nonmedical support to help patients as they start and continue on treatment as prescribed. Call **1-833-583-7399** or visit **AmgenByYourSide.com** to initiate enrollment for your patient by submitting the Patient Enrollment Form (PEF).

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

Please see Important Safety Information on next page and accompanying Full Prescribing Information or visit TEPEZZAhcp.com.



CPT® Drug Administration Codes ⁶		
Physician Office and Hospital Outpatient Department	96413	Highly complex drugs, including biologic agents or chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
	96415	Highly complex drugs, including biologic agents or chemotherapy administration, intravenous infusion technique; each additional hour (list separately in addition to code for primary procedure)
	96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
	96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (list separately in addition to code for primary procedure)
Specialty Pharmacy Providers	99601	Home infusion/specialty drug administration, per visit (up to 2 hours)

Use of appropriate billing codes for claims submissions is essential for reimbursement of TEPEZZA and its corresponding services. Please check with the payor to verify codes and special billing requirements. Amgen does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

CPT Copyright 2023 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association. CPT, Current Procedural Terminology.

IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients' hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

ADVERSE REACTIONS

The most common adverse reactions (incidence $\geq 5\%$ and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, weight decreased, nail disorders, and menstrual disorders.

Please see accompanying Full Prescribing Information or visit [TEPEZZAhcp.com](https://www.tepezza.com) for more information.

References: **1.** Centers for Disease Control and Prevention. ICD-10-CM tabular list of diseases and injuries. Accessed July 24, 2023. https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD10CM/2023/icd10cm-Tabular-Index-2023.zip **2.** TEPEZZA (teprotumumab-trbw) [prescribing information] Horizon. **3.** Centers for Medicare & Medicaid Services. Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) application summaries and coding decisions. Accessed July 24, 2023. <https://www.cms.gov/files/document/2020-hcpcs-application-summary-quarter-2-2020-drugs-and-biologicals.pdf> **4.** Centers for Medicare & Medicaid Services. July 2023 alpha numeric HCPCS file. Published July 11, 2023. Accessed July 24, 2023. <https://www.cms.gov/files/zip/july-2023-alpha-numeric-hcpcs-file.zip> **5.** Centers for Medicare & Medicaid Services. Medicare and Medicaid Programs CY 2023 payment policies under the Physician Fee Schedule and other changes to Part B payment and coverage policies; Medicare Shared Savings Program. Accessed July 24, 2023. <https://www.federalregister.gov/documents/2022/11/18/2022-23873/medicare-and-medicare-programs-cy-2023-payment-policies-under-the-physician-fee-schedule-and-other> **6.** American Medical Association. 2023 CPT® Professional Edition. Chicago, IL: American Medical Association; 2022.